Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Concurrent Chemoradiotherapy (Cisplatin-based)
Treatment for Nasopharynx cancer
Typical Dosage: 66-70 Gy radiation in 30-35 fractions with weekly Cisplatin 40 mg/m2 or 100 mg/m2 every 3 weeks for 2-3 cycles.
Effectiveness
85%
Safety Score
25%
Clinical Trials
12
Participants
30K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
66-70 Gy radiation in 30-35 fractions with weekly Cisplatin 40 mg/m2 or 100 mg/m2 every 3 weeks for 2-3 cycles.
Time to Effect
During and immediately after treatment (weeks to months)
Treatment Duration
6-7 weeks
Evidence Quality
HIGHConfidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$5,000
Monitoring:$20,000
Side Effect Mgmt:$15,000
Total Annual:$40,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTQALYs Gained
2
Outcome-Based Costs
Cost per Responder
$47,058
Cost per Remission
$53,333
Prescription Access Economics
Risk Assessment
Requires Monitoring
YesNeeds lab work/checkups
Concurrent Chemoradiotherapy (Cisplatin-based) Outcomes
for Nasopharynx cancer
Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+85%
Remission Rate
+75%
Common Side Effects
Mucositis
+80%
Xerostomia (dry mouth)
+90%
Dermatitis (radiation)
+85%
Nausea/Vomiting
+70%
Fatigue
+80%
Neutropenia
+40%
Nephrotoxicity
+25%
Dysphagia
+60%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
10 active trials recruiting for Concurrent Chemoradiotherapy (Cisplatin-based) in Nasopharynx cancer
Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT
NCT05628922RECRUITINGPHASE2
198 participants
INTERVENTIONAL
Shanghai, China
Started: Jul 2, 2022
Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma
NCT03919552RECRUITINGPHASE3
482 participants
INTERVENTIONAL
Guangzhou, China
Started: Jan 31, 2018
Sapylin Versus Dexamethasone Inhalation for CCRT-Induced Oral Mucositis in Nasopharyngeal Carcinoma
NCT07327216RECRUITINGPHASE3
180 participants
INTERVENTIONAL
Zhanjiang, China
Started: Aug 15, 2022
Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy
NCT07328841RECRUITINGPHASE3
456 participants
INTERVENTIONAL
Guangzhou, China +11 more
Started: Nov 18, 2025
Nituzumab (Taixinsheng ®） A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Combined Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinomatreatment of Locally Advanced Nasopharyngeal Carcinoma
NCT05508347RECRUITINGPHASE2
170 participants
INTERVENTIONAL
Chengdu, China
Started: Apr 20, 2022
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
NCT06239727RECRUITINGPHASE3
593 participants
INTERVENTIONAL
Fuzhou, China +25 more
Started: Mar 1, 2024
Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma
NCT07362979RECRUITINGPHASE2
243 participants
INTERVENTIONAL
Dongguan, China +3 more
Started: Mar 12, 2026
Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial
NCT07340515RECRUITINGPHASE3
300 participants
INTERVENTIONAL
Jinan, China
Started: Dec 15, 2025
Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy
NCT06092957RECRUITINGPHASE3
504 participants
INTERVENTIONAL
Guangzhou, China
Started: Oct 9, 2023
Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.
NCT06675214RECRUITINGPHASE3
586 participants
INTERVENTIONAL
Zhuhai, China
Started: Jul 30, 2024